Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price target of $24.75 for the company and are forecasting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned Verona Pharma PLC American Depositary Share an industry rank of 123 out of 265 based on the ratings given to its competitors.

Several equities analysts recently weighed in on VRNA shares. SunTrust Banks, Inc. started coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. They issued a “buy” rating and a $26.00 target price for the company. Stifel Nicolaus started coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. They issued a “buy” rating and a $22.00 target price for the company. Jefferies Group LLC reissued a “buy” rating and issued a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, July 25th. Finally, Wedbush started coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. They issued an “outperform” rating and a $25.00 target price for the company.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) opened at 12.28 on Wednesday. Verona Pharma PLC American Depositary Share has a 52 week low of $11.03 and a 52 week high of $17.50. The stock has a 50 day moving average of $14.21 and a 200-day moving average of $14.01. The firm’s market capitalization is $78.84 million.

WARNING: “Zacks: Verona Pharma PLC American Depositary Share (VRNA) Receives Consensus Rating of “Strong Buy” from Brokerages” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/12/zacks-verona-pharma-plc-american-depositary-share-vrna-receives-consensus-rating-of-strong-buy-from-brokerages-updated.html.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.